These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33836616)

  • 1. Loss of expression of both miR-15/16 loci in CML transition to blast crisis.
    Lovat F; Gasparini P; Nigita G; Larkin K; Byrd JC; Minden MD; Andreeff M; Carter BZ; Croce CM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
    Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
    Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
    Ko TK; Javed A; Lee KL; Pathiraja TN; Liu X; Malik S; Soh SX; Heng XT; Takahashi N; Tan JHJ; Bhatia R; Khng AJ; Chng WJ; Sia YY; Fruman DA; Ng KP; Chan ZE; Xie KJ; Hoi Q; Chan CX; Teo ASM; Velazquez Camacho O; Meah WY; Khor CC; Ong CTJ; Soon WJW; Tan P; Ng PC; Chuah C; Hillmer AM; Ong ST
    Blood; 2020 Jun; 135(26):2337-2353. PubMed ID: 32157296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia.
    Bhattacharyya J; Mihara K; Yasunaga S; Tanaka H; Hoshi M; Takihara Y; Kimura A
    Ann Hematol; 2009 Apr; 88(4):333-40. PubMed ID: 18781299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proto-oncogene expression varies over the course of chronic myeloid leukemia.
    Vidović A; Janković G; Colović M; Tomin D; Perunicić M; Bila J; Marković O; Bosković D
    Hematology; 2008 Feb; 13(1):34-40. PubMed ID: 18534064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis.
    Zhang B; Zhao D; Chen F; Frankhouser D; Wang H; Pathak KV; Dong L; Torres A; Garcia-Mansfield K; Zhang Y; Hoang DH; Chen MH; Tao S; Cho H; Liang Y; Perrotti D; Branciamore S; Rockne R; Wu X; Ghoda L; Li L; Jin J; Chen J; Yu J; Caligiuri MA; Kuo YH; Boldin M; Su R; Swiderski P; Kortylewski M; Pirrotte P; Nguyen LXT; Marcucci G
    Nat Commun; 2023 Sep; 14(1):5325. PubMed ID: 37658085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
    Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
    Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
    Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
    Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients.
    Mirza MAB; Guru SA; Abdullah SM; Rizvi A; Saxena A
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2379-2383. PubMed ID: 31450909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients.
    Hernández-Boluda JC; Cervantes F; Colomer D; Vela MC; Costa D; Paz MF; Esteller M; Montserrat E
    Exp Hematol; 2003 Mar; 31(3):204-10. PubMed ID: 12644017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cadherin-13 in primary and blast crisis chronic myeloid leukaemia: declining expression and negative correlation with the BCR/ABL fusion gene.
    Mu HJ; Xie R; Shen YF; Jiang YQ; Zeng YJ
    Br J Biomed Sci; 2009; 66(1):20-4. PubMed ID: 19348122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
    Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
    Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
    Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
    Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.
    Lakshmikuttyamma A; Takahashi N; Pastural E; Torlakovic E; Amin HM; Garcia-Manero G; Voralia M; Czader M; DeCoteau JF; Geyer CR
    J Hematol Oncol; 2009 Jul; 2():28. PubMed ID: 19602237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.